Related Experiment Video

Updated: May 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives

Marc-Olivier Timsit1, Laurence Albiges, Arnaud Méjean

  • 1Department of Urology, Hôpital Européen Georges Pompidou and Hôpital Necker, AP-HP, Paris, France.

Expert Review of Anticancer Therapy
|December 21, 2012
PubMed

Insights

Neoadjuvant targeted therapy for renal cell carcinoma is under investigation for safety and efficacy. While feasible, current drugs show limited tumor downsizing, suggesting use in clinical trials for advanced cases.

Area of Science:

  • Oncology
  • Nephrology

Background:

  • Targeted therapies have shown efficacy in metastatic renal cell carcinoma.
  • Investigating neoadjuvant strategies for locally advanced or nonresectable renal cell carcinoma is a growing area of research.

Purpose of the Study:

  • To evaluate the safety and efficacy of neoadjuvant targeted therapies in renal cell carcinoma.
  • To assess the potential for tumor downsizing and organ-sparing surgery.

Main Methods:

  • Literature review of relevant studies.
  • Inclusion of data from clinical trial databases and conference abstracts.

Main Results:

  • Neoadjuvant approach in renal cell carcinoma appears feasible and safe.
  • Currently available targeted therapies demonstrate a limited response rate of 10% for major tumor downsizing.
  • No significant tumor reduction observed for organ-sparing surgery.

Conclusions:

  • Neoadjuvant targeted therapy for renal cell carcinoma is safe but shows limited efficacy in tumor downsizing.
  • Consideration for neoadjuvant therapy should be restricted to clinical trials or as a test in locally advanced patients.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...